Chantix, a new stop-smoking drug that partially activates nicotine receptors in the brain, has arrived on the U.S. market.
USA Today says the new drug is different from other products because it levels out the peaks and dips from the roller coaster of nicotine addiction.
In clinical trials, about 22 percent of patients who took Chantix in clinical trials were still not smoking after a year. Thomas Glynn, director of cancer science at the American Cancer Society, told USA Today that fewer than 5 percent of smokers who try to quit on their own can last a year without a cigarette.
The newspaper said Acomplia, a drug available in Europe for weight loss, also has shown potential for helping smokers quit but it has not been approved for use in the United States.
Copyright 2006 by United Press International
Related stories:
Research suggests that cigarettes' power may not be in nicotine itself
There may be a very good reason why coffee and cigarettes often seem to go hand in hand. A Kansas State University psychology professor's research suggests that nicotine's power may be in how it enhances other experiences. For a smoker who enjoys drinking coffee, the nicotine may make a cup of joe even better. And that may explain why smoking is so hard to quit.
Genes may determine which smoking cessation treatment works best
Kicking the habit may soon become easier for the nation’s 45 million smokers. For the first time, researchers have identified patterns of genes that appear to influence how well individuals respond to specific smoking cessation treatments.
Quit smoking message not getting air time in mental health care
People with mental illness are not receiving the support they need to stop smoking, despite high rates of nicotine dependence and deaths from cardiovascular and respiratory illnesses.
Curing addiction with cannabis medicines
Smokers trying to quit in the future could do it with the help of cannabis based medicines, according to research from The University of Nottingham.
FDA: New warning needed for Chantix
The U.S. Food and Drug Administration Friday called for increased awareness of the health risks of the smoking cessation drug varenicline.
UCSD Researchers Find Young Adults More Likely to Quit Smoking Successfully
Young adults are more likely than older adults to quit smoking successfully, partly because they are more likely to make a serious effort to quit, say researchers at the Moores Cancer Center at the University of California, San Diego.
Nicotine-alcohol interaction impacts learning, could have implications for addiction treatment
The interaction between nicotine and alcohol, two of the most abused and co-abused drugs, can impact a person’s ability to learn and could have implications for treating addiction, according to researchers at Temple University.
New genetic research into nicotine addiction shows promise for personalized treatment
Whether a smoking-cessation drug will enable you to quit smoking may depend on your genes, according to new genotyping research from the Centre for Addiction and Mental Health (CAMH). The study, published in the September issue of the journal
Biological Psychiatry, found that the enzyme known to metabolize both the smoking cessation drug bupropion and nicotine is highly genetically variable in all ethnicities and influences smoking cessation.